Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer

被引:1
|
作者
Garcia, Ainhoa [1 ,2 ]
Torres-Ruiz, Sandra [2 ]
Vila, Laura [2 ]
Villarroel-Vicente, Carlos [1 ,2 ]
Bernabeu, Alvaro [1 ]
Eroles, Pilar [2 ,3 ,4 ]
Cabedo, Nuria [1 ,2 ]
Cortes, Diego [1 ]
机构
[1] Univ Valencia, Dept Pharmacol, Valencia 46100, Spain
[2] Univ Clin Hosp Valencia, Inst Hlth Res INCLIVA, Valencia 46010, Spain
[3] Univ Valencia, Dept Physiol, Valencia 46010, Spain
[4] Ctr Biomed Network Res Canc CIBERONC, Madrid 28019, Spain
来源
RSC MEDICINAL CHEMISTRY | 2023年 / 14卷 / 11期
关键词
DRUG DISCOVERY; APOPTOSIS; GENISTEIN; FAMILY; INHIBITORS; ESTROGEN; PATHWAY;
D O I
10.1039/d3md00385j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Synthesis of three series of 2-aminopropyl derivatives containing a benzopyran nucleus was performed to evaluate their performance against triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-436) and normal breast epithelial cells (MCF10A). For the three series, the cytotoxic activity was as follows: N-methylated derivatives (tertiary amines) 5b, 6b, and 7b > secondary amine benzopyrans 5, 6, and 7 > quaternary amine salts 5c, 6c, and 7c > free phenolic derivatives 5a, 6a, and 7a. The structure-activity relationship showed the importance of the presence of an amine group and a p-fluorobenzyloxy substituent in the chromanol ring (IC50 values from 1.5 mu M to 58.4 mu M). In addition, 5a, 5b, 6a, and 7b displayed slight selectivity towards tumor cells. Compounds 5, 5a, 5b, 6, 6a, 6c, 7, and 7b showed apoptotic/necrotic effects due to, at least in part, an increase in reactive oxygen species generation, whereas 5b, 5c, 6b, 7a, and 7c caused cell cycle arrest in the G1 phase. Further cell-based mechanistic studies revealed that 5a, 6a, and 7b, which were the most promising compounds, downregulated the expression of Bcl-2, while 5b downregulated the expression of cyclins CCND1 and CCND2. Therefore, 2-aminopropyl benzopyran derivatives emerge as new hits and potential leads for developing useful agents against breast cancer.
引用
收藏
页码:2327 / 2341
页数:15
相关论文
共 50 条
  • [21] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [22] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [23] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [24] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
  • [25] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [26] Insights into the Targeting Potential of Thymoquinone for Therapeutic Intervention Against Triple-negative Breast Cancer
    Barkat, Md Abul
    Harshita
    Ahmad, Javed
    Khan, Mohammad Ahmed
    Beg, Sarwar
    Ahmad, Farhan Jalees
    CURRENT DRUG TARGETS, 2018, 19 (01) : 70 - 80
  • [27] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [28] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [29] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [30] Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer
    Abdelmalek, Carine M.
    Hu, Zexi
    Kronenberger, Thales
    Kublbeck, Jenni
    Kinnen, Franziska J. M.
    Hesse, Salma S.
    Malik, Afsin
    Kudolo, Mark
    Niess, Raimund
    Gehringer, Matthias
    Zender, Lars
    Witt-Enderby, Paula A.
    Zlotos, Darius P.
    Laufer, Stefan A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (06) : 4616 - 4632